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With high cancer survival rates been so often dependent on earlier detection, molecular imaging 
presents a particularly useful approach in cancer screening. However, the current imaging technology 
required to carry out such detailed examinations often involves the use of harmful radiation and/or very 
expensive equipment. Therefore, the demand for a new non-invasive and inexpensive imaging modality 
that is safe enough to allow for more frequent screening to take place (both before and after cancer 
treatment) continues to be of great importance (Buccafusca, Proserpio, Tralongo, Rametta Giuliano, & 
Tralongo, 2019).  
High frequency ultrasound imaging is a non-invasive, non-ionising, portable and inexpensive imaging 
modality that can be used in conjunction with small diameter nanoparticles (10-100 nm) to move 
ultrasound imaging from the restrictions of the blood pool into small tumour masses. 
Silica nanoparticles between 10-100nm in diameter were employed in this work to investigate the 
specific acoustic properties of silica nanoparticle material. The particle size distribution of the particles 
within a tissue mimic was characterised and acoustic measurements were taken using a 50MHz 
broadband transducer. The ultrasound attenuation data acquired in this work was not indicative of any 
relationship between the specific material properties of the silica nanoparticles employed and high 
frequency ultrasound. However, the development of the early stage experimental design outlined in this 
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Chapter 1: Contrast Enhanced Diagnostic Imaging: Towards Safer 
and More Cost-Effective Population Screening 
 
1.1 Submicron contrast enhancing nanoparticles (<100 nm dia.), a neglected 
but important aspect of contrast enhanced ultrasound imaging. 
 
The International Agency for Research on Cancer reported 9.6 million deaths from cancer in 
2018 (IARC, 2018). An estimation of cancer survival rates of the most commonly occurring 
cancers, as provided by the Office for National Statistics anticipatedly revealed the survival 
rates of most cancers to be significantly increased if the cancer is detected at its early stage 
(Hawkes, 2019). In Hawkes (2019), results of the National Statistics report are reviewed to 
reveal that the highest one year cancer survival rates are found in melanoma, prostate cancer 
and breast cancer; which is largely due to the high percentage of prostate cancer and breast 
cancer being diagnosed at early stages (Agide, Sadeghi, Garmaroudi, & Tigabu, 2018; Hall, 
Schulthsiss, Farino, & Wong, 2015). Although breast cancer carries a high chance of been 
curable if detected in its early stages, breast cancer continues to be one of the biggest causes 
of cancer deaths worldwide (WHO, 2008). Liver, lung and colorectal cancers were all found to 
have one year survival rates that dropped significantly between detection at stage 1 and 
detection at stage 4 however, almost half of all lung cancers are not diagnosed before it has 
reached the most advanced stages (Hawkes, 2019). The most extreme decline in survival 
rates was found to be in liver cancers that are diagnosed between stage 2 (69.1% one year 
survival rate) and stage 3 (39.4% one year survival rate) (Hawkes, 2019) allowing 
hepatocellular carcinoma (HCC) to take its place as the third biggest cancer killer in the world 
(WHO, 2008). However, improved screening methods such as those described by Poustchi et 
al. (2011) highlight an opportunity to reduce the rate of mortality from HCC by increasing the 
frequency of screening procedures. Indeed, it can be deduced that most commonly occurring 
cancers would carry a higher chance of survival if physicians were able to diagnoses disease 
in its earlies stages, frequently before the onset of indicative symptoms. However, such design 
of an effective population screening method requires very careful consideration (Cucchetti, 
Cescon, Erroi, & Pinna, 2013). Time consuming methods that require the use of expensive 
equipment and/or processes, run the risk of becoming economically unviable to be carried out 
on large volumes of patients. Low sensitivity methods leading to inconclusive results or 
misdiagnosis, requiring further medical investigation increases exposure to the risks 
associated with such procedures and will inevitably incur addition costs that would otherwise 




Although NHS statistics highlight an increase in survival rates when compared to previous 
years, it is evident that there are still many cancers that are been diagnosed too late (Hawkes, 
2019). Significant time-lags between diagnosis by screening and diagnosis through symptoms 
emphasises the need for more readily available screening technology, capable of detecting 
the earliest stages of cancer (Hatch et al., 2016). Widespread screening of high-risk 
populations has the potential to be a powerful lifesaving tool. However, careful considerations 
must be given to the possibility of exposing patients to the potential of harm that exceeds the 
potential benefit (Goodwin, Sheffield, Li, & Tan, 2016). 
With high cancer survival rates been so often dependent on the early detection, molecular 
imaging presents a particularly useful approach in cancer screening. However, the current 
imaging technology required to carry out such detailed examinations often involves the use of 
harmful radiation and/or very expensive equipment. Therefore, the demand for a new non-
invasive and inexpensive imaging modality that is safe enough to allow for more frequent 
screening to take place (both before and after cancer treatment) continues to be of great 
importance (Buccafusca, Proserpio, Tralongo, Rametta Giuliano, & Tralongo, 2019).  
High frequency ultrasound is a non-invasive, non-ionising, portable and inexpensive imaging 
modality that has the potential to provide both functional and anatomical information in real-
time. However, the only contrast agents currently approved and used in clinical molecular 
ultrasound imaging are microbubbles with diameters between 1-3 m. Although these 
particles are often described as nanoparticles, their micron-scale diameters limit their ability 
to extravasate the blood pool into solid tumour masses and are therefore limited to only 
vasculature-based studies. The use of smaller contrast agent nanoparticles <100 nm 
diameter, have the potential to move US imaging from the restrictions of the blood pool into 
small tumour masses and therefore, enabling earlier detection of cancer. In addition to this, 
the smaller particles also have the ability to be retained within the area of interest long enough 
to be imaged without replenishment; something that microbubbles are currently unable to 
deliver on. 
One of the major reasons why most of the newly developed nanosized contrast agents do not 
make it to clinical trials is the lack of in vivo quantification techniques available to fully assess 
the biocompatibility and toxicity of such nanoparticles in vivo. More research is needed 
towards developing a new imaging technology that is capable of quantifying nanosized 




Therefore, this aspect of contrast enhanced imaging should be studied because doing so 
would drive development of new ultrasound imaging technology towards earlier detection and 
quantification of cancer. 
 
1.2 Scope of the dissertation 
 
The objectives of this work are to investigate the specific acoustic properties of a nan-sized 
material that can be used as contrast agents in clinical diagnostic imaging. 
In order to achieve the objective, there are several limitations that need to be overcome. An 
imaging medium such as a tissue mimic will be developed with a well-defined particle size 
distribution to enable more accurate quantification of any acoustic response. 
Chapter 2 reviews the background of currently available contrast enhanced imaging modalities 
and their ability to detect early stage cancer. Molecular imaging modalities that are not 
currently used in medical imaging are reviewed for their potential to translate into clinical 
applications. The current status of contrast enhanced ultrasound is reviewed, with focus on 
the use of NPs <300 nm as contrast agents for early cancer imaging diagnostics. 
Chapter 3 describes the experimental set up and techniques used to prepare a monodispersed 
nanoparticle population of potential contrast agent <20 nm in diameter within a tissue mimic, 
and the ultrasound investigations that were undertaken. 
Chapter 4 describes the results of preliminary investigations involving characterising the 
particle size distribution of the silica nanoparticles on diluting, heating and incorporating into 
the gelatine-based tissue mimic. 





2: A review of contrast enhanced diagnostic imaging: current status 




In this chapter, a background of currently available diagnostic imaging modalities and their 
ability to detect early stages of cancer are discussed, with a view to better understanding the 
underlying principles that make these modalities a good diagnostic imaging tool. Future 
prospects for molecular imaging been translated to clinical practice are evaluated and the 
cost-effectiveness of each modality assessed. A brief overview of the many different contrast 
agents that are currently used in practice and those upcoming as the next generation of 
contrast agents are discussed, in addition to the more recent research efforts towards the use 
of nano sized particles as contrast agents in diagnostic imaging. The current status of contrast 
enhanced ultrasound imaging using high frequency ultrasound is reviewed and the major 
limitations that need to be overcome for this to be translated into clinical practice are identified. 
With this information in hand, an alternative approach to the more commonly used high 
frequency imaging systems that employ contrast agents >1 m is suggested as the basis for 
this work. 
 
2.2 Introduction to medical imaging 
 
Medical imaging is a valuable diagnostic tool that enables anatomy and physiology to be 
visualized and studied for any irregularities or abnormalities that may be present in a patient’s 
body. According to the diagnostic imaging dataset provided by the NHS statistical release in 
2018, 42.7 million medical imaging tests were carried out in UK in 2018; of which, over a 
quarter of all tests requested by general practitioners was to diagnose or discount cancer 
(NHS, 2018). Medical imaging involves the passing an imaging probe such as x-ray or 
ultrasound through a patient’s body to generate contrast data that can be exploited by an 
imaging modality to form images. The most commonly used imaging probes in clinical 
diagnostics include X-rays (radiography, CT, CR, DR, fluoroscopy and DSA), ultrasonic 
pressure waves (US), light (optical fluorescence imaging), nuclear medicine (PET and 
SPECT) and magnetic fields and radio waves (MRI, MRA, MRS and DTI). Although there are 
a growing number of medical imaging modalities that differ in their ability to provide detection 




accuracy and long term safety, none are capable of providing complete structural and 
functional information independently (Sharma et al., 2008). Therefore, selecting the right 
imaging modality that employs the most appropriate imaging probe depends strongly on the 
particular medical situation and disease to be studied (Wolbarst, Capasso, & Wyant, 2013). 
For high volume early cancer diagnostic screening, detection sensitivity and specificity 
towards the disease is key. However, the imaging capability required to detect small early 
tumour formation in vivo continues to be a great challenge.  
 
In relatively recent years, molecular imaging has given birth to a wide range of imaging 
modalities that can be employed for the detection of early tumours. Molecular imaging is the 
in vivo visualisation, characterisation and quantification of biological processes at a cellular to 
molecular level. With a view to obtaining greater diagnostic accuracy and/or to enable greater 
imaging depths, the additional use of carefully designed contrast agents (CAs) has become a 
widely researched area, spanning across many disciplines. The development of such CAs that 
can help to visualise cancer proliferation and smaller tumour masses by exploiting the unique 
physical, chemical and biochemical properties thereof have enabled physicians to better study 
the indicative metabolic processes and characteristics of cancer microenvironments. 
The correct selection of CAs for the imaging modality employed allows for CAs to significantly 
increase the degree of contrast, allowing for greater imaging depths and/or accuracy  (Wu, 
Huang, Jiang, & Jiang, 2014). All modalities of contrast enhanced imaging require a contrast 
agent that is able to selectively identify the target tissue and accumulate within. However, the 
designing of a CA that is capable of specifically reaching the target cells and retaining there 
long enough to be detected presents a number of complex challenges (Chen & Chen, 2010). 
In addition to this, for imaging modalities with low sensitivity, the use of CAs with the multiple 
contrast functionalities may also be required if adequate levels of signal amplification are to 
be achieved (Debbage & Jaschke, 2008). The aim is therefore, to achieve the highest contrast 
as possible with high resolution and penetration depth for a minimal amount of contrast agent.  
 




Despite the discovery of X-ray imaging taking place over a century ago and well before the 




used imaging modality for obtaining medical images world-wide (Wolbarst et al., 2013). With 
22.9 million X-ray images and 5.51 million CT scans carried out in the UK in 2018, the use of 
electromagnetic waves in medical imaging and diagnostics continues to increase (NHS, 
2018). 
The most commonly used X-ray imaging modalities for the diagnosis of cancer are CT and 
mammographic imaging. Mammographic imaging is currently the most frequently used 
imaging modality for breast cancer screening (Miranda & Pertuz, 2019) and has also showed 
great potential in more recent years for breast cancer risk assessment (Gastounioti, Conant, 
& Kontos, 2016). However, mammography screening remains a very complex and relatively 
expensive imaging modality (Agide et al., 2018). In addition to this, mammography has in 
recent years received a number of criticisms for over diagnosis in women with dense breast 
tissue (Kuhl, 2018). Therefore, research efforts have now turned to alternative modalities for 
breast cancer screening modalities. In recently published article by Mori et al. (2018), MRI was 
shown to be powerful imaging tool in distinguishing between malignant and benign lesions, 
particularly in breast lesions. 
CT plays a vital role in pathology diagnostics due to its ability to produce static 3-D visualisation 
of x-ray attenuation by tissues at an unlimited depth with exceptional spatial resolution (Liao 
et al., 2019). One of the biggest advantages of CT scan images over MRI is its high spatial 
resolution, which enables the visualisation of objects with poor contrast from within a patient. 
Offering a spatial resolution of up to 0.625 mm in the z-axis and 0.5 mm (approx.) in the x to 
y-axes, CT imaging offers spatial resolution up to the 1-2 mm typically associated with MRI 
(Lin & Alessio, 2009). Relatively recent developments in targeted high-performance CAs such 
as those described by Liao et al. (2019) shows a promising ability to provide greater contrast 
in CT images, with higher sensitivity. However, the contrast resolution provided with some MR 
modalities is still significantly superior to that of CT imaging. 
The spatial resolution of CT images is largely dependent on the dose of X-ray administered. 
Higher doses result in higher signal to noise ratios therefore making it easier to visualise low 
contrast physiology (Goldman, 2007). With increasing concerns associated with the safety of 
radiation exposure in medical imaging (Mahesh & Morin, 2018), significant efforts have now 
turned to low-dose CT as a more promising screening modality (Bach, Brawley, & Silvestri, 
2018; Smith et al., 2014). Recent developments in atomisation of lung cancer detection and 
characterisation  (Kavitha, Shanthini, & Sabitha, 2019) in addition to advances in low dose 
CT technology, as reviewed by Callister and Janes (2017), makes for a convincing argument 
towards the use of low-dose CT in nationwide lung cancer screening. However, questions still 




imaging equipment, possibly rendering such screening economically unviable (Callister & 
Janes, 2017; Obaro, Burling, & Plumb, 2018). 
 
2.3.2 Magnetic fields and radio waves  
Whole body MRI modalities are now commonly used in  full body examinations for early 
tumour detection (Pasoglou, Michoux, Larbi, Van Nieuwenhove, & Lecouvet, 2018). MRI is a 
nonionizing imaging modality that provides high-resolution 3-D anatomical images via the 
exploitation of hydrogen nuclei within a patient’s body. By applying a strong magnetic field to 
the tissue of interest, the hydrogen nuclei within the tissue become uniform both in rotation 
and polarity. Once the uniform state has been established, short pulses of radio waves are 
passed through the tissue (the MRI sequence), causing the hydrogen nuclei to absorb energy 
and rotate out of equilibrium. After the radio wave transmission is eliminated, the nuclei are 
able to relax and energy is emitted (Schlemmer, 2009). Differences in the magnitude of energy 
released in addition to the time taken to return back to the original rotation is then visualised 
as contrast in diagnostic images, capable of superior soft tissue contrast to that of CT 
(Dommaschk et al., 2019). 
Relatively recent MR modalities such as dynamic contrast enhanced MRI (DCE-MRI), arterial 
spin labelling (ASL), diffusion weighted imaging (DWI) and MR spectroscopic imaging (MRSI) 
are all able to deliver additional dynamic information in relation to the functional properties of 
malignant lesions (Schlemmer, 2009). This dynamic imaging modality is therefore providing 
valuable diagnostic information relating to the physiological status of pathology that is 
comparable to that provided in nuclear medicine (Wolbarst et al., 2013). In the recent work 
carried out by Morabito et al. (2019), DCE-MRI was demonstrated to be a good imaging 
modality for distinguishing between tumour reoccurrence and post-therapy necrosis. This type 
of capability in a diagnostic imaging modality would undoubtedly serve as a valuable tool in 
the monitoring of cancer progression, treatment planning and therapy. DCE-MRI is a real-time 
imaging modality which involves the administration of imaging CAs to enhance contrast and 
improve the quality of the resultant images. The additional benefit of DCE-MRI to static MRI 
imaging modalities is its ability to dynamically image vasculature. Because newly formed 
neovascular associated with cancer growth differs from the neovascular of normal tissues, this 
enables DCE-MRI to be used to further improve the detection of cancer (Du, Fu, Ren, Li, & 
Guo, 2019). In a sensitivity study carried out by Zhang, Zhang, Wang, Chen, and Sui (2019) 
of 47 articles reporting diagnostic data of liver metastases using DWI,MRI and CE-MRI, it was 
estimated that for liver metastases in lesions ≥ 10 nm in diameter, the sensitivity of DWI, MRI 




to produce such strong magnetic fields required for all MRI modalities, in comparison to other 
commonly used imaging modalities, remains very expensive. In addition to this, high doses of 
CAs are required to be administered, often with adverse effects. 
MRI CAs are employed in CE-MRI for their ability to accelerate the relaxation times of the 
surrounding hydrogen nuclei, providing enhanced differentiation between surrounding tissues 
(Brown, Cheng, Haacke, Thompson, & Venkatesan, 2014). Among the most commonly used 
CAs in clinical applications of CE-MRI are gadolinium and iron oxide based particles (Na, 
Song, & Hyeon, 2009). Currently, the CAs used in CE-MRI clinical diagnosis are not sensitive 
enough to generate images with a high enough resolution to resolve a single cell; therefore 
limiting its application in very early disease assessments (Sharma et al., 2008). However, the 
development of a new generation of CAs have emerged in recent years exhibiting an 
increasing ability to accumulate in micro sized tumours with high levels of specificity. For 
example, in the work published by Du et al. (2019), a manganese-oxide mesoporous silica NP 
(85.4 ± 14.8 nm) was found to specifically target a rat prostate tumour within 5-10 nm of the 
malignant lesion. 
When compared to CEUS imaging, DCE-MRI has been shown to have superior performance 
in the detection of prostate cancer and prediction of its aggressiveness (Baur et al., 2018). In 
a study carried out by Muhi et al. (2011) the diagnostic images of a solitary hepatic metastasis 
using CE-MRI, weighted MRI, DWI, B-mode US, CEUS and contrast enhanced CT (CE-CT) 
were compared for contrast and accuracy of diagnostic information. As shown in figure 1, the 
CE-MRI image obtained (a) via a gadolinium based CAs was able to provide an increased 
degree of contrast within the hepatic metastasis lesion (indicated by the arrow). When 
compared to the images produced via weighted MRI and DWI (b & c), these images gave less 
contrast and therefore less diagnostic accuracy than that of CE-MRI. However, in the images 
obtained using CE-CT (e) and B-mode and CEUS (d), the metastasis lesion was undetected. 
In great contrast to this  however, a more recent investigation carried out by (Furrer et al., 
2019) suggests that CEUS may be capable of outperforming CE-CT and CE-MRI for the 
diagnostic of renal masses. In this work Furrer et al. (2019) pooled together 1483 articles 
relating to the final diagnosis of benign and malignant renal masses for analysis. The results 
of this analysis suggest that CEUS gave a significantly higher level of sensitivity than CE-CT, 
reporting values of 0.96 (95% confidence interval 0.94-0.98) and 0.90 (95% confidence 
interval 0.86-0.93) respectively, and also a significantly higher sensitivity to that of CE-MRI, 







Figure 1. A pathologically confirmed hepatic metastasis (arrow) imaged using (a) Gd-EOB-MRI, (b) weighted MRI, (c) 
DWI, (d) B-mode US and CE-US, (e) CE-CT (Muhi et al., 2011). 
 
2.3.3 Nuclear medicine 
PET and SPECT imaging provides 3-D tomographic images via the use of tissue targeted 
carrier molecules containing radioisotopes. After the employed radioisotope tracers are 
administered to a patient, information depicting their location and concentration are processed 
to generate a 3-D visualisation of their distribution within a tissue of interest (Massoud & 
Gambhir, 2003). The active incorporation of radiotracers within bodily tissues therefore, unlike 
CT and MRI, offers the advantage of providing metabolic and functional information. The 
fundamental difference between PET and SPECT is that PET imaging modalities employ the 
use of positron emitting tracers whereas SPECT modalities differ in their employment of 
gamma-ray emitting tracers. SPECT carries a longer radiation exposure times than that of 
PET due to PET possessing higher energy and stronger photons, enabling a quicker exit from 
the body (LeVine, 2010). However, the correct selection of imaging modality to be used for a 
particular type of medical investigation depends essentially on the type of radiotracer that will 
deliver the most relevant diagnostic information. 
The major purpose of PET scans is to detect and monitor cancer and tumours down to a 
cellular level. The direct targeting of cancer cells via glucose carrier molecules containing the 




using PET (Adekola, Rosen, & Shanmugam, 2012). This highly detailed metabolic information 
is a powerful tool in the monitoring of tumour progression and response to therapy. However, 
one major limitation of PET is that most anatomic structures in the images produced are either 
are poorly depicted or completely absent (Saif, Tzannou, Makrilia, & Syrigos, 2010). 
Therefore, most modern PET scanners also incorporate the use of CT to provide the additional 
anatomical information required for accurate diagnosis. Contrast enhanced CT imaging in 
addition to PET enables the better differentiation of the anatomical structures therefore, 
improved lesion localisation and characterisation can be made resulting in more accurate 
diagnostic information. In an article by Antoch, Freudenberg, Beyer, Bockisch, and Debatin 
(2004), CE-CT images were compared to that of PET, PET/CT and PET/CE-CT after a 47 
year old female patient was administered with 18F-FDG and CT contrast agent. As shown in 
figure 2, the hepatic metastasis of a 47 year old female patient was not distinguished in the 
CE-CT image (A). The PET image (B) shows increased glucose metabolism of the hepatic 
metastasis and therefore increased uptake of tracer however, very poor visibility of anatomical 
features was obtained. The combined PET/CE-CT image (C) visualises the accurately 
localised hepatic metastasis lesion and a biopsy device within viable tumour tissue (D) (Antoch 
et al., 2004). 
Figure 2. (A) CE-CT, (B) PET, (C) PET/CE-CT, (D) PET/CE-CT showing a biopsy device in hepatic metastasis lesion 
(Antoch et al., 2004). 
 
Dual PET/CT modalities offers high diagnostic value in the diagnosis of many different types 




diagnosis (Parisi et al., 2017). However, with both PET and CT involving exposing the patient 
to harmful radiation, efforts have now turned to lower dose PET/CT such as that described in 
the work by Molinos et al. (2019). As MRI offers as a non-ionising alternative to CT with 
comparable ability to determine local tumour extent, this type of multimodal PET/MRI 
approach contains a great degree of optimism for higher volume population screening. In the 
work carried out by Beiderwellen et al. (2015) it was found that both PET/CT and PET/MRI 
offer equivalently high diagnostic value in the diagnosis of recurrent pelvic malignancies. 
PET/MRI however, was found to offer a higher level of discrimination between benign and 
malignant lesions. In addition to this, Beiderwellen et al. (2014) found that whole-body MRI 
with PET/MRI also offered superior lesion visibility in bone metastasis images, with the added 
benefit of reduced radiation dose. Considering the reduced radiation dose superior lesion 
discrimination, PET/MRI offers the opportunity for a more desirable alternative multimodality. 
Currently, PET is only diagnostic molecular imaging modality routinely used in medical 
diagnostics. Although PET/CT offers highly detailed metabolic information with high spatial 
resolution of anatomical features, PET is a static and very expensive imaging modality that 
uses highly ionising radiation. Therefore, PET is not a desirable choice for frequent post 
therapy monitoring or population screening (Conversano et al., 2011). Non-ionising 
alternatives to PET for early cancer detection is therefore of increasing importance. Such 
alternatives include optical imaging, dynamic CE-MRI and CEUS.  
 
2.3.4 Optical imaging 
Photoacoustic imaging (PAI) is a non-invasive, non-ionizing molecular imaging system that 
combines light with US to detect the consequential acoustic pulses arising from optical 
absorption. Visible light in the form of short laser pulses are used to induce transient heating 
within a patient’s bodily tissues, causing a thermoelastic expansion of the tissue and 
subsequent generation of ultrasonic waves. The sound waves produced are detected by an 
US receiver and the data is exploited to produce high contrast images with high optical and 
spatial resolution, capable of providing structural, functional and biological information 
(Sharma et al., 2008). Recent developments in exogenous CAs exhibiting strong photothermal 
properties have been demonstrated to provide excellent contrast down to a molecular level. 
However, most of these particles are currently not permitted in clinical applications due to their 
cytotoxicity not yet been fully understood (Ho et al., 2014). 
Optical imaging modalities typically achieve a spatial resolution of 1m at 1mm depth however, 
unlike fluorescence tomography (FMT), the exploitation of the photoacoustic effect enables 




comparable spatial resolution to that of US and still maintaining a high level of optical 
resolution (Dang et al., 2019; Ryu et al., 2013; Zhang et al., 2019). Although PAI has been 
shown to be an effective tool in molecular imaging at microscopic resolutions, unlike US, PAI 
application in deep tissue regions is limited by the attenuation characteristics of the light 
source (Witte, Karunakaran, Zuniga, Schmitz, & Arif, 2018). However, a recent comparison 
study between the different PAI imaging configurations currently available, carried out by Attia 
et al. (2019) reports that a penetration depth of up to 8.4 cm can be achieved in a chicken 
breast if the correct imaging configuration is employed. 
PAI CAs are of particular interest in early cancer detection due to their small NP size, enabling 
them to accumulate in tumour tissue via the EPR effect. Gold nanoparticles (NPs) are one the 
most commonly researched PAI CAs due to its high photothermal conversion efficiency and 
biocompatibility (Sztandera, Gorzkiewicz, & Klajnert-Maculewicz, 2019). Photothermal 
conversion is the conversion of light energy (supplied by the PAI light source) to heat energy, 
inducing transient heating (X. Li et al., 2018). In addition to the strong photothermal properties 
of gold NPs, the negative surface charge also allows for surface functionalization and 
biomodification (McNamara & Tofail, 2016), allowing the NPs to be more easily modified to 
carry out a specific function. However, synthesis and functionalization of the gold nanorods 
still requires a number of challenges to be overcome. Concerns arise from the synthesis 
method which currently allows for large variations in particle size, and so significantly 
impacting yield (Shah, Imran, & Ullah, 2019). Therefore, the economic viability of producing 
precious metal NPs with low yield may limit the imaging system in its use as a high-volume 
population screening modality. In addition to this, the laser technology required to produce the 
sharp pulses of light capable of inducing deeper transient heating are generally very large and 
relatively expensive. However, in the paper written by Erfanzadeh and Zhu (2019) it was 
assessed that lower-cost light source alternatives can be explored. In addition to this, when 
compared to CE-MRI, MRI technology is significantly more expensive. Therefore, there 
continues to be an increase in demand for new nanoparticle technology that can further 
enhance the contrast obtained via PAI with a view to maintaining its characteristic high 
contrast and high resolution images at deeper penetration depths (Shah et al., 2019). This 
type of imaging technology would significantly enhance cancer detection by offering a non-
invasive, non-ionising imaging system with the ability to detect small early cancer lesions via 





2.3.4 Sound waves 
Diagnostic ultrasound is a non-invasive, non-ionising imaging modality that employs sound 
waves to generate echo signal data that can be visualised as contrast between bodily tissues 
(sonograms). With most clinical frequency US scanners having the ability to image in a variety 
of different imaging modes, US can be readily used in the pre-diagnosis of a wide range of 
different diseases quickly, easily and using relatively inexpensive equipment (Mortimore & 
Mayes, 2019). However, the spatial resolution achieved using US is considerably less than 
that achieved by MRI and limitations in its use arise from sound wave inefficiency at passing 
across tissue/air or tissue/bone interfaces (Wolbarst et al., 2013); something an X-ray modality 
such as CT would deliver superior contrast in. In soft tissues however, low radiological 
differences between different soft tissues limits the contrast delivered using CT therefore, the 
contrast obtained using US is superior at imaging soft tissues than CT. Therefore, 
ultrasonography has advantages over CT in cost, lack of ionising radiation and improved 
spatial resolution however, CT images have superior diagnostic accuracy. 
However, the interpretation of B-mode sonographic images is often described as been 
operator dependent. Correct identification and interpretation of differing features that can 
occur in a sonogram requires a great amount of skill and experience. In addition to this, these 
features can also vary significantly in sensitivity, specificity and positive and negative 
predictive values (Rowe, Osorio, Likhterov, & Urken, 2017). Therefore, the identification of 
sonographic features and interpretation thereof still lacks in an adequate degree of sensitivity 
and specificity to be able to independently diagnose or rule out malignancy (Lim, 2019; Melany 
& Chen, 2017). However, although B-mode imaging cannot be used to distinguish between 
malignant and benign tissue (Guo, Raghu, Durand, & Hooley, 2018), its ability to detect areas 
of interest for further investigation safely, quickly and cheaply still makes US a go-to choice in 
population screening (Kamal, Hamed, Mansour, Mounir, & Abdel Sallam, 2018; Ronot et al., 
2018; Y. Wang et al., 2019). Therefore, the widespread use of sonography as a non-invasive, 
cost-effective high-volume screening tool for the monitoring and identification of pathological 
changes continues to be in great demand. 
CEUS was first developed in the 1990’s via the first generation of CAs consisting of non-
enveloped air/oxygen echogenic microbubbles. In more recent years however, the most 
frequently utilised US CAs consist of phospholipid or protein stabilised hydrophobic gas core 
microbubbles (Song et al., 2018; L. Y. Wang & Zheng, 2019). When microbubbles are exposed 
to low amplitude US pulses, the microbubble is compressed and expanded with the positive 
and negative pressure phases of the pulse in an oscillatory fashion. At low acoustic pressures, 
the bubble response is linear, resulting in low echo signal gain and therefore low contrast. At 




linear, resulting in an increasing degree of contrast that can be visualised. However, as the 
acoustic pressure is increased, the stability of the microbubble becomes increasingly 
compromised leading to bubble fission and eventually complete destruction of the microbubble 
(Mulvana et al., 2017). 
Currently, there are two main types of CEUS imaging systems that are employed in clinical 
CEUS, single-pulse and multi-pulse imaging sequences. Each imaging systems has been 
designed to have increased sensitivity to specific microbubble behaviour. In single-pulse 
imaging, the microbubble is able to be distinguished from tissue based on the frequency 
content of the received echoes. The acoustic response of bodily tissue consists of a narrow 
range of scattered frequencies. However, the acoustic response of a microbubble is very 
broadband therefore, the received echo frequencies that are outside the range of the tissue 
echo can be selectively filtered to produce an image. The visualised contrast produced in the 
image will therefore correspond to the distribution and concentration of CA within the tissue 
and will only include minimal visualisation of tissue backscatter. This is the basis for harmonic 
(Menigot & Girault, 2016), super harmonic (Y. Li et al., 2016) and subharmonic imaging (Park, 
Kim, Cho, & Seo, 2016). Multi-pulse imaging sequences differ from single-pulse in that it 
exploits the different non-linear oscillations of a specific type of microbubble when exposed to 
a collection of US pulses with differing characteristics (Chong, Papadopoulou, & Dayton, 
2018). Examples of multi-pulse imaging sequences include phase inversion and amplitude 
modulation (Satir & Degertekin, 2016). One major limiting factor for both single-pulse and 
multi-pulse imaging modalities however, is the poor signal-to-noise (SNR) ratio in deeper 
tissue regions. Due to the decreased SNR, a higher degree of bubble response is required to 
achieve the same degree of contrast. This increase in bubble response is achieved by 
increasing the acoustic pressure that is applied. However, increasing the acoustic pressure 
results in rapid decrease in signal duration due to bubble destruction therefore, the 
microbubbles will continuously need to be replenished. With the signal duration under typical 
imaging protocols currently standing below 5 minutes (Abenojar et al., 2019), the even more 
rapid signal decay under high acoustic pressures this limits the imaging time available for 
deeper tissue imaging. However, a new strategy recently proposed by Gong, Song, and Chen 
(2018) has suggested a way in which this particular challenge can be overcome. A 
combination of CEUS sequences with longer transmission pulses and multiplane-wave 
compounding method was used to improve the signal-to-noise (SNR) ratio in deeper tissues 
without increasing the acoustic pressure. In this work, it was found that the method employed 
had significantly improved the SNR of CEUS imaging without increasing the acoustic pressure. 
In addition to the imaging system design in CEUS, statistical systems such as the CEUS liver 




improve the true-negative classification of HHC diagnosis. Such systems, in conjunction with 
more accurate imaging powered by CAs and system design are therefore showing exciting 
new ways in which cancer detection and diagnosis can be taken into high volume population 
screening (Bertolotto et al., 2018). However, although the clinical use of CEUS with 
microbubbles has increased considerably in the past 5 years, there are still many issues to be 
overcome regarding their in vivo stability and polydisperse size distribution. When a 
microbubble is exposed to an US pulse, bubble coalescence and gaseous core dissolution 
can occur. This results in reduced imaging time durations and half-life circulation time (Song 
et al., 2018). Stabilisation methods such as the lipid shell-stabilised perfluoro propane recently 
proposed by Abenojar et al. (2019) have been demonstrated to prolong in vivo stability 
however, many efforts have now turned to hard-shell microbubbles as an alternative method 
to improve in vivo stability of US CAs. The ‘harder’ the shell, the less sensitive the bubble 
becomes to US exposure at low acoustic pressures. However, hard shell microbubbles are 
more capable of withstanding higher acoustic pressures and therefore improving in vivo 
stability and SNR in deeper tissue. Another common problem associated with microbubble 
CAs is the polydisperse characteristics of those commercially available and approved; 
typically 1000-3000 nm in diameter (Gnyawali et al., 2017). As smaller microbubble sizes exhibit 
less echogenic behaviour,  monodisperse microbubbles are more desirable than polydisperse 
characteristics (Pellow, Goertz, & Zheng, 2018). However, the synthesis of monodisperse 
microbubbles that have the circulation half-life times required for medical imaging continuous 
to be a challenge (Gnyawali et al., 2017).  
Unlike the CAs used in CE-MRI and CE-CT, CEUS microbubbles are too large to extravasate 
the blood pool and enter the interstitial space of solid tumours (Chong et al., 2018). As newly 
developed vasculature of cancer lesions differs to that of normal tissue, vascularity studies 
using CEUS such as that carried out by Kummer et al. (2018) have shown to be a good 
indicator of cancer size and pathological severity. However, one major limitation of CEUS in 
molecular imaging is the lack of sub-micron sized US CAs that have the ability to extravasate 
out from the vasculature into the interstitial fluid (Lim, 2019; Zlitni & Gambhir, 2018). However, 
the synthesis/generation of stabilised, monodispersed microbubbles with strong echogenic 
properties and long lifetimes is very technically challenging (Perera et al., 2017; Son, Min, 
You, Kim, & Kwon, 2014). 
 
2.4 Contrast targeting strategies 
CAs used in diagnostics can be either exogenous or endogenous. Many of the CAs that have 




microbubbles for CEUS, hard shell particles and particles that incorporate signal generators 
such as iron oxide, gadolinium, fluorine, iodine, bismuth, radionucleotides, quantum dots, and 
metal nano-clusters (Debbage & Jaschke, 2008). The specific targeting of CAs to malignant 
tissue is area of research that has expanded rapidly in the past 20 years, resulting in many 
new CA designs emerging with unique physiochemical properties such as size, shape and 
surface chemistry (Barua, 2018; Ruoslahti, 2012; Shobaki, Sato, & Harashima, 2018; Wilhelm 
et al., 2016). However, the efficiency of a CA reaching a target lesion such as a solid tumour 
continues to be a great challenge. A comprehensive analysis carried out by Wilhelm et al. 
(2016) of nanoparticle delivery efficiency to tumours over a 10 year period between 2005-2015 
found that only a median of 0.7% of the administered dose of NP was able to reach a solid 
tumour. NP less than 5nm in hydrodynamic diameter were found to be excreted by the renal 
clearance pathway and NP >5nm taken up by phagocytic cells of the mononuclear phagocytic 
system (MPS), eliminating 99% of the injected dose. However, NP with hydrodynamic 
diameters <100nm were found to have a higher delivery efficiency than NP >100nm. In 
addition to this, NP with neutral zeta potentials (defined as -10 to +10 mV) were also found to 
have a greater delivery efficiency than those with negative (<10mV) and positive (>10mV) zeta 
potentials. Active targeting strategies such as the use of NPs with functionalised ligands 
complementary to the target sites were found give greater delivery efficiencies than passive 
targeting strategies such as enhanced permeability and retention effect (EPR), and rod 
shaped NPs exhibited higher efficiencies than spherical, plate and other shapes (Wilhelm et 
al., 2016). 
Preclinical research, as discussed in Sulheim et al. (2018), has demonstrated that NPs and 
macromolecules have the ability to accumulate in solid tumours due to the EPR effect. 
However, the EPR effect is still been disputed by many as an effective targeting strategy. The 
EPR effect is a passive tumour targeting strategy which allows nano-sized particles and 
molecules to accumulate within tumour tissue to a greater extent than in that of normal tissues. 
When tumour cells multiply to reach a cluster size of 2-3 mm, the growth factor for the 
formation of new blood vessels (angiogenesis) is triggered to meet the new oxygen and 
nutrition demands of the growing tumour mass. The newly formed neovascular differs from 
the neovascular of normal tissues in that it is irregular in shape, dilated, reduced (or absent) 
smooth muscle layer and possess defective endothelial cells that are poorly aligned or 
disorganised with large fenestrations (Iyer, Khaled, Fang, & Maeda, 2006). These anatomical 
defects allow for excessive leaking of blood plasma components (such as contrast probe NPs) 
into the tumour tissue. Furthermore, tumour tissue experience poor lymphatic clearance and 
reduced venous return and so the extravasated plasma components are retained for a 




local concentrations of NPs smaller than a pore size of tumour endothelium (typically 380-
780nm) are able to temporarily reside within the tumour tissue (Conversano et al., 2011; Iyer 
et al., 2006). However, NPs with diameters less than 10 nm are also able to extravasate from 
normal capillaries therefore, the use of NPs is limited to >10 nm in order to discriminate 
between normal and leaky capillaries (Wilhelm et al., 2016) and allow for the passive infiltration 
of tumours without infiltrating the surrounding normal tissues (Pellow et al., 2018). 
Although active targeting strategies have been shown in many investigations to be the most 
efficient method of delivery  (Wilhelm et al., 2016), these investigations mostly compare this 
strategy to studies of non-targeted particles with diameters >380 nm. As decreasing particle 
diameter increases extravasation, NP CAs with diameters <100 nm are more likely to be 
dominated by the EPR effect (Vallet-Regi, Colilla, Izquierdo-Barba, & Manzano, 2017). 
Therefore, smaller NP sizes would result in less non-specific retention, giving a greater 
differentiation between malignant and benign tissue. 
Poorly targeted CAs in vivo can dramatically reduce the degree of contrast obtained in all 
imaging modalities. High level background noise caused by CAs with non-specific retention 
can overwhelm the signal gain and essentially drown it out. For high signal to noise ratios to 
be achievable therefore, relatively large volumes of CAs are required to build up in within or 
around the specific site of interest for the images produced to be diagnostically accurate. 
Molecular imaging NPs that are small enough to extravasate into blood capillaries and 
come equipped with surface functionalisation to improve stability and biocompatibility, as 
well as target specific cells within the body are now emerging as the next generation of NPs 
(Chong et al., 2018; Feinstein et al., 2010; Marcelo, Lodeiro, Capelo, Lorenzo, & Oliveira, 
2020; Martinez et al., 2010; Vallet-Regi et al., 2017). These NPs have already shown great 
promise in their application of early disease detection however, complete studies that consider 
the biodegradability, biocompatibility and toxicological effects of such NPs are particularly 
rare. Therefore, the field still lacks in sufficient understanding of in vivo NP behaviour (Marcelo 
et al., 2020). More contrast agent specific imaging technology that has the capability to image 
such NPs with high resolution is therefore of great importance if in vivo detailed assessments 







2.6 High frequency CEUS imaging 
 
Although non-targeted microbubbles are been used increasingly in clinical US molecular 
imaging, BR55 is currently the first and only clinical grade molecularly targeted US CA that 
has been FDA-approved (Abou-Elkacem, Bachawal, & Willmann, 2015; Willmann et al., 
2017). The BR55 microbubble consists of a gas core of N2 and C4F10 stabilised by a 
phospholipid shell that is functionalised with a heterodimer peptide specific for VEGFR2 
(Smeenge et al., 2017). BR55 has been successfully applied in a first safety and feasibility 
study for prostate cancer detection and VEGFR2 expression in breast and ovarian lesions 
(Abou-Elkacem et al., 2015; Willmann et al., 2017). However, due to the diameter of the BR55 
CA and other FDA-approved non-targeted microbubbles (typically 1-4m dia.), these US CAs 
are limited to only vasculature based studies such as; inflammation imaging, inflammatory 
bowel disease, inflammation in atherosclerosis and oncological imaging (Abou-Elkacem et al., 
2015). In addition to this, there are still many issues to be overcome regarding microbubble in 
vivo stability and polydisperse size distribution. Therefore, many efforts have now turned to 
hard-shell microbubbles as an alternative method to improve in vivo stability and give better 
control over particle size distribution. 
 
Figure 3. A schematic of an attached BR55 microbubble (Smeenge et al., 2017). 
 
The most frequently used hard shell microbubbles consist of biodegradable polymers and 
silica (Song et al., 2018). The most commonly researched hard-shell NP material used in US 




to its unique properties including controllable particle size, good biocompatibility and 
biodegradability (Marcelo et al., 2020). Nano-porous silica shells are advantageous due to 
their smaller uniform sizes and low toxicity (Martinez et al., 2010). Mesoporous silica in 
particular has gained an increasing amount of attention in more recent years due to its high 
surface area to volume ratio that can be exploited by surface functionalisation and theragnostic 
applications (Vallet-Regi et al., 2017). 
Hollow nanoparticles made from silica and polymer shells exhibit good echogenic properties 
by their ability to expand and contract under low acoustic pressures without coalescence or 
destruction (De Jong, Bouakaz, & Frinking, 2000). However, unlike echogenic soft shell 
microbubbles, harder shell microbubbles and NPs exhibit significantly lower echogenic 
properties therefore, the contrast obtained by such hard shell microbubbles and NPs is still 
highly dependent on concentration (Song et al., 2018).  
 
The imaging contrast obtained via hard shell particles with little echogenic response is 
obtained through differences in attenuation between the particles and surrounding tissue. The 
greater the concentration of CA within the area of interest, the greater the degree of 
attenuation and therefore the greater degree of contrast gained in the images produced. 
Attenuation by absorption occurs when a particle oscillates under acoustic pressure. The 
differences in density between a NP and its medium causes motion of the particle with respect 
to the medium and shear wave friction is induced, resulting in losses of acoustic energy 
(Dukhin & Goetz, 2010). In grey scale imaging algorithms, the more highly absorbing regions 
will translate into less received signal compared to surrounding tissues therefore, areas of 
high CA populations will appear to be darker than those of surrounding tissue. In contrast to 
absorption, attenuation by scattering involves the redirection of acoustic energy rather than 
loss. The redirection of acoustic energy allows for the reflection to be received by a transducer 
as a signal gain. The signal gain is therefore translated as contrast by providing brighter 
shades of grey in grey scale algorithms. When a hard-shell particle is exposed to an acoustic 
pulse, attenuation due to absorption and scattering are distinctly separated in the frequency 
domain. For fixed particle sizes, absorption will dominate at low frequencies and scattering at 
high frequencies. For particles < 1 m, scattering is insignificant at frequencies < 100 MHz. 
Therefore, for particles < 3 m, losses in acoustic energy (attenuation) is dominated by 
absorption with negligible acoustic losses occurring from scattering with particles < 1 m 
(Dukhin & Goetz, 2010). Therefore, particles within the size range of 1-3 m fall within the 
transition stage between the two mechanisms resulting in both absorption and scattering 
occurring simultaneously. The consequence of this is that signal gain from scattering would 




However, for particle sizes < 1 m or > 3 m, the degree of contrast obtained will be largely 
dependent on the local concentration of particles within the area of interest. Although, for 
particle sizes < 1 m, the high frequency US pulses required would also be highly attenuated 
by other structures within the biological tissue and significantly decreases the resolution at 
greater imaging depths. However, US attenuation is function of both depth and material 
therefore, by investigating the specific acoustic behaviour of a specific material of NP (< 1 
m), signal processing can be employed to narrow the frequency range employed to that at 
which the specific material of NP shows the highest degree of attenuation contrast with 
surrounding tissue. In contrast to the multi modal US scanners commonly placed in clinical 
settings, this type of US imaging modality will therefore be one that has a narrower range of 
application. However, as a non-invasive, non-ionising, inexpensive imaging modality with the 
potential to provide both functional and anatomical information in real-time, this particular type 
of imaging system shows immense promise. Therefore, the use of hard-shell NPs as US 
contrast agents with diameters < 100 nm and > 10 nm (the size of a healthy blood capillary 






When applied to early cancer detection, molecular imaging can be used to both detect and 
locate tumour masses as well as provide the specific metabolic information required to assess 
the state of progression and/or response to therapy (Chong et al., 2018). With PET/CT and 
PET/MRI been the only molecular imaging modalities that are currently available in clinical 
practice, high frequency US imaging presents its self as a promising alternative imaging 
modality with the potential to provide both functional and anatomical information in real-time. 
High frequency US is a non-invasive, non-ionising, portable and inexpensive imaging modality 
that can be used in conjunction with small diameter silica NPs (10-100 nm) to move US 
imaging from the restrictions of the blood pool into small tumour masses. By investigating the 
acoustic properties of silica NPs with monodisperse particle size distributions, the specific 
relationship between the attenuation of silica at high frequencies can be deduced. This 
information will enable more specific signal processing and therefore increase the diagnostic 








In order to investigate the specific acoustic properties of Silica NPs a broadband range of 
frequencies are required. A high frequency broadband transducer (centre frequency 50 MHz) 
will experience return signal losses due to absorption attenuation of the silica NPs under 
investigation. The signal loss in the time domain can then be transformed into the frequency 
domain using the Fourier transform for the silica NP attenuation to be calculated. Data 
spanning across a range of frequencies as provided by the broadband transducer can be used 
for further data analysis to investigate the acoustic relationship between the silica NPs and 
employed acoustic energy. 
In order to accurately investigate the degree of attenuation caused by a monodispersed size 
range of silica NPs between 10-20 nm in diameter, the size distribution of the NPs employed 
in the US investigation must first be characterised. The use of tissue mimicking mediums are 
commonly used in US investigations to more accurately model the acoustic environment in 
which the NPs are held. However, in order for this method to be used, the particle size 
distribution of the silica NPs within the tissue mimic also requires characterisation. Dynamic 
light scattering instrumentation provides data for particle size distribution and zeta potential of 
colloidal dispersants (NPs). The data provided can be used to evaluate the particle size 
distribution and mean average particle size of the silica NP within the gelatine tissue mimic. 
However, as the principle of the measurements are based on Brownian motion, any testing of 
the NP/gelatine solution before it has solidified. 
Small angle X-ray scattering is an analytical technique that measures the intensity of scattered 
x-rays as a function of scattering angle. When a sample is placed in front of an x-ray beam, 
the incident x-rays are scattered by the particles at characteristic angles. The scattered x-rays 
are detected and the angle at which the incident x-ray beam has been scattered is used to 
characterise the sample using a number of different data processing methods. The information 
provided will be indicative of the size, structure and surface properties of NP within the sample. 
This technique can therefore be used to support the data provided by the dynamic light 
scattering instrumentation. 
Commercially available LUDOX colloidal silica is supplied in relatively high concentrations 
compared to those that are required in this investigation therefore, the commercially available 




for the US investigation. Ensuring that the stability of a colloidal system after a dilution has not 
been compromised, dynamic light scattering investigations can be used to identify any 
changes in particle size (indicative of aggregation) and zeta potential (indicative of the 
electrophoretically mobile particles). As before, small angle x-ray measurements can also 
provide information relating to the particle size of the dispersant as well as support the dynamic 
light scattering measurements.  
 
3.2 Materials used 
 
▪ LUDOX HS-40 colloidal silica (SiO2), 40 wt.% in H2O, supplied by Sigma-Aldrich 
(product number 420816). 
▪ Dr.Oetker powdered gelatine batch number 2-82-033056 
▪ Borokapillaren 2.0 mm borosilicate glass mark tubes (80 mm length) supplied by 
Capillary Tube Suppliers UK 
▪ Vegetable oil spray - Sainsburys 
▪ BRAND macro 2.5 mL UV-cuvettes, Cat. No. 7591 70 
 
3.1        Equipment used 
 
▪ Malvern Instruments Limited, Malvern zetasizer model ZEN3600, serial no. 
MAL1053758 
▪ Bruker small angle x-ray scattering instrument 
▪ Jenway 3510 pH meter model 3510, serial no. 61512 
▪ Brookfield viscometer model RVDV-II+, serial no. RT58636 
▪ Tektronix DPO 7254 Digital phosphor oscilloscope – Supplied by the National Physical 
Laboratory, Tedington 
▪ Olympus 5073PR pulse/receiver - Supplied by the National Physical Laboratory, 
Tedington 
▪ Zeal spirit in glass thermometer series IP-39C-SIMILAR, serial no. 1848220 - Supplied 
by the National Physical Laboratory, Tedington 
▪ Olympus Panametrics-NDTV358 50 MHz/0.25 transducer, serial no. 855206 
(transducer) - Supplied by the National Physical Laboratory, Tedington 
▪ Olympus Panametrics-NDTV358 50 MHz/0.25 transducer, serial no. 852201 




▪ Ultrasound measurements tank as provided by the National Physical Laboratory, 
Teddington UK 
 
3.4 Experiments performed 
 
3.4.1 Method 1: Staged dilution of 30.7 vol% colloidal SiO2 to 1 vol% with H2O (pH ~10) 
 
30.7 vol% colloidal SiO2 was diluted to a concentration of 1 vol% in 1 vol% stages until a final 
concentration of 1 vol% was achieved. Samples were taken at each stage of dilution and were 
placed into a zetasizer instrument to obtain zeta potential and particle size distribution data. 
The Malvern zetasizer software measurement settings were pre-defined via a standard 
operating procedure. The measurement settings that were defined are: 
▪ Measurement temperature: 25C 
▪ Temperature equilibration time: 120 seconds 
▪ Dispersant refractive index: 1.33 
▪ Dispersant viscosity: 0.8872 cP 
▪ Particle refractive index: 1.590 
▪ Particle absorption: 0.01 
Zetasizer measurements were taken using a 2.5 mL sample placed into a 2.5 mL disposable 
UV-cuvette. Zeta potential measurements were taken via the Malvern universal dip cell 
provided with the instrumentation. 
1) 45 mL of 30.7 vol% colloidal SiO2 was drawn from its storage container using a glass 
volumetric pipette and placed into a 200 mL glass beaker. The beaker was placed into an 
ultrasonic bath to be sonicated for 20 minutes before a 2.5 mL sample was taken. The sample 
taken was immediately placed into the zetasizer instrument to measure the zeta potential and 
particle size distribution of the 30.7 vol% colloidal SiO2. The temperature, viscosity and pH of 
the liquid remaining in the beaker was recorded. 
2) The first dilution stage was to dilute the original 30.7 vol% colloidal SiO2 to 30 vol% using 
0.99 mL of H2O. The pH of the deionised H2O that was used to dilute the colloidal silica was 
measured and adjusted using NaOH in order to match the pH of the colloidal SiO2 to be within 
±0.50 of the pH of the colloidal SiO2. 0.99 mL of the pH adjusted H2O was added to the 200 
mL beaker containing the 45 mL colloidal SiO2 dropwise in 0.1 mL droplets over 5 minutes. 
The solution was then left in the ultrasonic bath for a further 20 minutes. After 20 minutes of 




to measure the zeta potential and particle size distribution of the new concentration, 30 vol% 
colloidal SiO2. The temperature, viscosity and pH of the liquid remaining in the beaker was 
recorded. 
3) The second dilution stage was to dilute the 30 vol% colloidal SiO2 to 29 vol% using 1.41 mL 
of the pH adjusted deionised H2O used in stage 1. Like stage 1, the H2O was added dropwise 
in 0.1 mL droplets over 5 minutes and left under sonication for 20 minutes before a 2.5 mL 
sample was taken. The sample taken was used to measure the zeta potential and particle size 
distribution of the solution made at 0 minutes out of the ultrasonic bath. The remaining 29 vol% 
solution was measured for temperature, viscosity and pH. 
4) Subsequent dilution sages were carried out to dilute the SiO2 concentration by a further 1 
vol% in each stage. Each subsequent dilution stage was carried out in the same order as that 
described in the first and second stage of dilution. The amount of H2O added at each stage 
was calculated as: 
volume of SiO2 remaining  after smapling (mL)
Desired concentration (vol%)
− total volume remaining after sampling (mL) (1) 
 
For example, the volume of H2O added for the first dilution was calculated to be: 
H2O required (mL) =
42.5 × 0.307
0.30
− 42.5 = 0.99 mL 
The 1 vol% staged dilutions were carried out until a final concentration of 1 vol% was achieved. 
5) In addition to the zeta potential and particle size distribution measurements that were taken 
at 0 minutes out of the ultrasonic bath, measurements at 1 hr, 2 hrs, 24 hrs, 72 hrs and 7 days 
were taken for concentrations of 30.7, 25, 20, 15, 10, 5 and 1 vol% solutions. 
 
3.4.2 Method 2: Dilution of 30.7 vol% colloidal SiO2 to a series of concentrations with 
H2O (pH ~10) 
 
Deionised H2O was used to dilute 30.7 vol% colloidal silica to a concentration of 1, 2, 3, 4, 5, 
10, 15, 20 and 25 vol%. The pH of the deionised H2O used was measured and adjusted using 
0.1 M NaOH in order to match the pH of the colloidal SiO2 to be within ±0.50 of the pH of the 
colloidal SiO2. 
For each desired concentration, the amount of H2O (pH ~10) and stock colloidal SiO2 (30.7 




Vol. of H2O required − Vol. of 30.7 vol% SiO2 required (2) 
Vol. of 30.7 vol% SiO2 required(mL) =
required conc. (vol%)
30.7 (vol%)
× required total vol. (mL) (3) 
For example, the volume of stock 30.7 vol% colloidal SiO2 required to make 200 mL of 1 vol% 
SiO2 concentration was calculated to be: 
Vol. of 30.7 vol% SiO2 required (mL) =
1
30.7
× 200 = 6.51 mL 
Zetasizer measurements were taken using a 2.5 mL sample placed in a 2.5 mL disposable 
UV-cuvette. Zeta potential measurements were taken via the Malvern universal dip cell 
provided with the instrumentation. The measurement settings were pre-defined via the 
software standard operating procedure defined in method 1 (section 3.4.1). 
1) The required volume of H2O (calculated by equations 2) + 2.5 mL was measured using a 
glass volumetric pipette and placed into a 200 mL beaker. The beaker containing the 
measured volume of H2O was placed under sonication in an ultrasonic bath for 20 minutes 
before a 2.5 mL sample was taken. The sample (containing H2O only) was placed inside the 
Malvern zetasizer for zeta potential and particle size measurements to be taken.  
2) The required volume of the 30.7 vol% colloidal SiO2 (calculated by equation 3) was added 
to the beaker containing the measured volume of pH adjusted H2O in approximately 1 mL 
droplets over a time period of 5 minutes. The beaker contents were left under sonication for a 
further 20 minutes before it was lifted out of the bath and placed onto the work top.  
3) The diluted colloidal silica liquid was measured for temperature, viscosity and pH. Samples 
of the liquid were taken at 0 minutes, 15 minutes, 30 minutes, 45 minutes, 2 hrs, 3 hrs, 24 hrs, 
72 hrs and 7 days out of the ultrasonic bath and were placed into the Malvern zetasizer for 
zeta potential and particle size measurements to be taken. 
 
3.4.3 Method 3: Dilution of 30.7 vol% colloidal SiO2 to a series of concentrations with 
H2O (pH ~7) 
 
Deionised H2O was used to dilute 30.7 vol% colloidal silica to a concentration of 1, 2, 3, 4, 5, 
10, 15, 20 and 25 vol%. The pH of the deionised H2O used was measured but was not adjusted 
to match the pH of the colloidal SiO2 as per methods 1 and 2. The pH of the H2O therefore 




desired concentration, the amount of H2O (pH ~7) and stock colloidal SiO2 (30.7 vol%) 
required was calculated by equations 2 and 3. 
Each colloidal SiO2 concentration was then prepared, sampled and measured using steps 1 
to 3 as per method 2 (section 3.4.2). 
Zetasizer measurements were taken using a 2.5 mL sample placed in a 2.5 mL disposable 
UV-cuvette. Zeta potential measurements were taken via the Malvern universal dip cell 
provided with the instrumentation. The measurement settings were pre-defined via the 
software standard operating procedure defined in Method 1 (section 3.4.1). 
 
3.4.4 Method 4: Dilution of 30.7 vol% colloidal SiO2 to a series of concentrations with 
H2O (pH 5.0) 
 
Deionised H2O was used to dilute 30.7 vol% colloidal silica to a concentration of 1, 2, 3, 4, 8, 
11, 15 and 20 vol%. The pH of the deionised H2O used was measured and adjusted using 0.1 
M HCl to pH 5.0. For each desired concentration, the amount of H2O (pH 5.0) and stock 
colloidal SiO2 (30.7 vol%) required was calculated by equations 2 and 3. 
Each colloidal SiO2 concentration was then prepared, sampled and measured using steps 1 
to 3 as per Method 2 (section 3.4.2). 
Zetasizer measurements were taken using a 2.5 mL sample placed in a 2.5 mL disposable 
UV-cuvette. Zeta potential measurements were taken via the Malvern universal dip cell 
provided with the instrumentation. The measurement settings were pre-defined via the 
software standard operating procedure defined in Method 1 (section 3.4.1). 
 
3.4.5 Method 5: Dynamic light scattering of colloidal SiO2 after heating to 55C 
 
Concentrations of 1, 2, 3, 4, 8, 11, 15 and 20 vol% colloidal SiO2 solutions were prepared using 
a stock 30.7 vol% colloidal SiO2 and deionised H2O. The pH of the deionised H2O used was 
measured and adjusted using a 0.1 M HCl to establish a H2O pH 5.0. For each desired 
concentration, the amount of H2O (pH 5.0) and stock colloidal SiO2 (30.7 vol%) required was 




1) The required volume of H2O (calculated by equation 2) was measured using a glass 
volumetric pipette and placed into a 200 mL beaker. The beaker containing the measured 
volume of H2O was placed under sonication in an ultrasonic bath for 20 minutes. 
2) The required volume of the 30.7 vol% colloidal SiO2 (calculated by equation 3) was added 
to the beaker containing the measured volume of H2O (pH 5.0) in approximately 1 mL droplets 
over a time period of 5 minutes. The beaker contents were left under sonication for a further 
20 minutes before it was lifted out of the bath and placed onto the work top. 
3) Measurements of temperature, viscosity and pH were taken at room temperature at 0 
minutes out of the ultrasonic bath. 
4) The beaker and its contents were placed onto a hot plate with magnetic stirrer and were 
heated to 55C. Measurements of temperature, viscosity and pH were taken at 55C. A 2.5 
mL sample was taken and placed inside the zetasizer instrument. Measurements of zeta 
potential and particle size distribution were recorded using the zetasizer equipment and 
software. The zetasizer measurements were carried out at 55C with an equilibration time of 
120 seconds, as pre-defined using a standard operating procedure within the zetasizer 
software. 
5) The solution was allowed to cool to 25C and measurements of viscosity, pH, zeta potential 
and particle size distribution were taken using the zetasizer instrument.  
 
3.5.6 Method 6: Small angle x-ray (SAX) measurements of colloidal SiO2 and SiO2 in 8 
wt.% gelatine 
 
1) Sample preparation. Colloidal SiO2 at concentrations of 1, 2, 3, 4, 8, 11,15 and 20 vol% 
were prepared as described in Method 4 (section 3.4.4). 
2) Using a glass pipette, approximately 0.5 mL of the H2O used to prepare the samples via 
method 4 was each loaded into a 2.0 mm borosilicate glass capillary tube as shown in Figure 
4. The capillary tube was then sealed using bee’s wax that was melted into the opening of the 





Figure 4: Bee’s wax, melted and decanted into the opening of a 2.0 mm borosilicate glass 
capillary tube containing H2O. 
 
3) Due to the high fail rate of the fragile capillaries when put under vacuum a second capillary 
containing the H2O used to prepare the samples was sealed via a second method. To seal the 
second capillary, the tube opening was held above a flame for approximately 5-10 seconds 
until the borosilicate glass at the end of the capillary had melted inwards and formed a seal. 
4) The sealed capillaries were placed onto a mount and secured in place with screws as shown 

















Figure 5: Borosilicate glass capillary containing H2O (left), BRUKER small ang x-ray instrument 
sample mount (right). 
 
5) The sample mount was placed within the vacuum chamber of the SAX instrument for data 
acquisition. An initial nomography was taken to locate the sample capillaries within the 
chamber as shown in figure 6. Once the capillary of interest had been located, the centre point 
of the sample was then located by determining the lowest point of intensity on the 
nomography, shown as the darker red regions in Figure 6. The X and Y coordinates of the 
centre of the sample was recorded and used as the co-ordinates for data acquisition. 
 
 






6) The measurement setting for the data acquisition were predefined using the SAX software 
as: 
Distance: 107.650 
Number of frames: 10 
Seconds per frame: 600 seconds 
7) The data acquisition as described in steps 1 – 6 was repeated for each concentration of 
colloidal SiO2, 1, 2, 3, 4, 8, 11, 15 and 20 vol%. 
8) The data acquisition as described in steps 1-6 was repeated for a 4 wt.% gelatine solution 
and an 8 wt.% gelatine solution containing a 1, 2, 3, 4, 8, 11, 15 and 20 vol% concentration of 
SiO2. 
 
3.4.7 Method 7: Preparation of 8 wt.% gelatine-based tissue mimics containing SiO2 
 
1) Colloidal SiO2 at concentrations of 1, 2, 3, 4, 8, 11,15 and 20 vol% were prepared as 
described in Method 4 (section 3.4.4). 
2) 62.5 mL of deionised H2O was measured using a glass pipette and placed into a 150 mL 
beaker. The beaker was placed onto a hot plate with magnetic stirrer and heated to between 
65-70C. Once the temperature was reached, 7g of gelatine crystals were added and the hot 
plate was turned off. The beaker was held on the hot plate with the magnetic stirrer operating 
until the gelatine crystals were dissolved. 
3) Once the gelatine solution was transparent to the eye, indicating that the gelatine crystals 
were dissolved, it was then carefully poured into a 10 cm diameter petri dish. Care was taken 
not to transfer any bubbles that had formed on the surface or any undissolved crystals that 
had stuck to the beaker walls. 
4) 17.5 mL of the prepared colloidal SiO2 concentration was injected into the solution using a 
5 mL syringe. As shown on the left of Figure 7, the injected 4 vol% SiO2 solution diffused into 
the gelatine solution on injection. The solution was agitated using the syringe needle to 
encourage mixing. Greater concentrations of colloidal SiO2 were less diffusive than lower 
concentrations and so a greater amount of mixing was required. The image shown on the right 
of Figure 7 shows an 8 vol% SiO2 solution been injected in the same manner as that shown 
in the 4 vol% on the left. However, bubbles were formed on mixing and the viscosity of the 




with increasing concentrations. As shown in figure 8, the highest concentration of SiO2 (20 
vol%) became very viscous compared to lower concentration and so a significant amount of 
air was trapped within the sample. 
 
 
Figure 7: The visible diffusion of 4 vol% colloidal SiO2 injected into 8 wt.% gelatine (left) and 8 
vol% colloidal SiO2 injected into 4 wt.% gelatine (right). 
 
 






5) The petri dish was placed into a preheated vacuum oven preheated at 50C. The sample 
was held within the oven at 50C under vacuum (~0.96 bar) for 1 hour. During this time, the 
bubbles trapped within the samples were drawn out. After 1 hour, the heat applied to the oven 
was turned off and the samples were left to cool under vacuum for another 1 hour. 
6) The samples were removed from the vacuum oven and stored in a refrigerator at 3C until 
required for further measurements (up to 12 hours). 
 
3.5.8 Method 8: Dynamic light scattering measurements of colloidal SiO2 in 8 wt.% 
gelatine. 
 
1) Colloidal SiO2 at concentrations of 1, 2, 3, 4, 8, 11,15 and 20 vol% were prepared as 
described in Method 4 (section 3.4.4). 
2) 62.5 mL of deionised H2O was measured using a glass pipette and placed into a 150 mL 
beaker. The beaker was placed onto a hot plate with magnetic stirrer and heated to between 
65-70C. Once the temperature was reached, 7g of gelatine crystals were added and the hot 
plate was turned off. The beaker was held on the hot plate with the magnetic stirrer operating 
until the gelatine crystals were dissolved. 
4) The beaker was taken off the hot plate and 17.5 mL of the prepared colloidal SiO2 
concentration was injected into the solution using a 5 mL syringe. The solution was agitated 
using the syringe needle to encourage mixing. 
5) The solution was allowed to cool to 25C at room temperature before a 2.5 mL sample was 
taken. The sample was transferred into a 2.5 mL disposable cuvette and placed into a 
zetasizer instrument for zeta potential and particle size distribution measurements to be taken. 
 
3.4.9  Method 9: Ultrasound attenuation measurements of gelatine-based tissue 
mimics containing SiO2 NPs with a 50 MHz centre frequency broadband transducer 
 
1) The US measurements tank was filled with de gassed water. 
2) Two 50 MHz transducers were clamped into place using the measurements tank brackets 
as shown in Figure 9. The two faces of the transducers were held in place ~5mm apart, facing 




as a receiver in receive mode and the transducer shown on the right-hand side of Figure 9 
was employed as the transducer to generate the US pulses. 
 
Figure 9: A 50 MHz transducer (right) and receiver (left) (picture taken at the ultrasound 
laboratory at the National Physical Laboratory, Teddington) 
 
3) The experimental set up was allowed to stand for 1 hour after set up to allow for any 
background noise and/or bubbles within the tank to be dissipated. 
4) To ensure that the transducer face was correctly aligned with the receiver, the receiver 
position was fixed in place and the power was switched on. The following power settings were 
set; 
▪ Gain: +19 
▪ PRF (Hz): 1K 
▪ Energy: 4 
▪ Damping: 8 




5) An alignment of the transducer face with the face of the receiver was carried out at minimum 
distance apart (horizontal delay 12.76 s). The transducer face was translated in the X and Y 
axis in order to locate the centre of the receiver face. The centre point on the receiver face is 
the point at which the voltage received is at its maximum. As shown in Figure 10, the voltage 
peak shown on the oscilloscope before translation (left) gave a lower peak to that received 
after the receiver centre was located (right). 
 
Figure 10: Wave form of the 50 MHz transducer before (left) and after (right) alignment with the 
centre of the receiver face. (picture taken at the ultrasound laboratory at the National Physical 
Laboratory, Teddington) 
 
6) Once the centre of the receiver was located, the transducer face was aligned parallel to the 
receiver face by rotating transducer and receiver about their centre point. As in step 5, the 
point at which the two faces are parallel is the point at which the highest voltage can be 
received. 
7) A second alignment of the transducer and receiver as described in steps 5 and 6 was 
carried out at maximum distance apart (horizontal delay 43.70 s). 
8) the thickness of each samples to be used in the US measurements was measured prior to 
been lowered into the measurement tank. The thickness measurements were taken at 4 
separate points on the sample using a digital thickness gauge and the average was taken. 
9) The first sample to be measured (gelatine reference sample) was secured onto the sample 




sample to be placed in-between. As shown in Figures 11 and 12, once the sample was 
lowered, the transducer face was brought as close as possible to the sample holder without 
obstructing the holder from been lifted out of the water. 
Figure 11: US receiver on left hand side of tissue mimic sample (picture taken at the ultrasound 
laboratory at the National Physical Laboratory, Teddington) 
Figure 12: US transducer on right hand side of tissue mimic sample (picture taken at the 




10) The energy setting was adjusted for data acquisition to; 
▪ Gain: +25 
▪ PRF (Hz): 1K 
▪ Energy: 4 
▪ Damping: 8 
▪ Mode 2 (isolates transmit and receive to give through transmission) 
10) For each sample, the following measurements were taken through the centre point of the 
sample, with 5000 scope averages; 
▪ Reference transmission (without sample in place) at 26 s horizontal delay 
▪ Sample through transmission at 26 s horizontal delay 
▪ Reference transmission (without sample in place) at 27 s horizontal delay 
▪ Sample through transmission at 27 s horizontal delay 
▪ Reference transmission (without sample in place) at 28 s horizontal delay 
▪ Sample through transmission at 28 s horizontal delay 
▪ Reference transmission (without sample in place) at 29 s horizontal delay 
▪ Sample through transmission at 29 s horizontal delay 
11) For samples of 0, 1, 3 and 8 Vol%, grid measurements were taken 2 mm apart from one 




Investigations into the stability of the colloidal silica dilutions at each stage of the tissue mimic 
synthesis was investigated. Dilutions of colloidal silica were carried out via a number of 
different methods in order to investigate the effects of pH, temperature and viscosity on the 
colloidal system.  
The pH of the colloidal silica (outsourced) used in the tissue mimic synthesis was pH 10 ±0.5. 
As the pH of gelatine is ~5.0, the effects of pH on the dilution of the original colloidal silica was 
investigated by altering the pH of the H2O used in the dilutions to pH 10 ± 0.5, pH 5.0 and pH 
7. Dynamic light scattering measurements were taken of each dilution with the different H2O 
solvents so that the data could be used to identify any changes in the aggregation state due 




To investigate the effects of heating the diluted colloidal silica during the tissue mimic 
synthesis, dynamic light scattering measurements were taken of the diluted colloidal silica 
after heating to 55C and then after allowing this to cool back down to 25C. The data provided 
was used to compare with the measurements taken at 25C without heating to identify any 
changes in aggregation state induced by the heating process. 
The PSD of the SiO2 NPs within the tissue mimic after synthesis was measured in order to 
define the mean particle size of silica NP used in the US investigations. The data provided 
was used to compare with the data of the colloidal silica before the addition of gelatine to 
investigate the effect of the synthesis method on the PSD. 
Small angle x-ray measurements were taken of the colloidal silica dilutions and gelatine 
containing SiO2 NPs in order to support the data obtained from the zetasizer instrument. 
US measurements were carried out using a broadband 50 MHz centre frequency transducer 
to investigate the attenuation of the silica NPs across a frequency range of 10-60 MHz. Each 
measurement was carried out with a reference measurement and at 4 separate horizontal 
delay distances to assure that the attenuation data collected was a direct function of the NPs 









Chapter 4: Results and discussion of preliminary investigations 




Before the contrast enhanced ultrasound measurements can be carried out the silica 
nanoparticles must first be prepared for imaging. Commercially available colloidal silica 
nanoparticles are available in significantly higher concentrations to that required in this work. 
Therefore, the colloidal silica was diluted to a range of concentrations that can be used in the 
synthesis of an acoustic tissue mimic. Tissue mimics are commonly used in research to model 
the behaviour of biological tissue. However, many for the publications that employ tissue 
mimics for contrast agent studies give little information on the particle size distribution of the 
particles therein. As the acoustic properties of nanoparticles can vary significantly with particle 
size, a full characterisation of the particle size distribution must first be carried out. With that 
information in hand, the acoustic investigations can be carried out under the assumption of 
monodisperse particles with a defined size distribution. 
 
4.2. Results and discussion 
 
The volumetric mean particle sizes measured using dynamic light scattering gave a mean 
particle size range of 5-20 nm. In the colloidal silica dilutions carried out via Method 1 and 
Method 2, the pH of the colloidal system was maintained by altering the pH of the deionised 
water used, to within ±0.5 of the colloidal silica. As changes in pH can lead to neutralisation of 
the surface charge of the silica NPs, the consequential decrease in electric repulsion, this 
allows for intermolecular interactions to dominate (Van der Waals) and aggregates are formed. 
However, as shown in Figures 13 and 14, the controlling of the pH in Methods 1 and 2, did not 
completely prevent aggregation therefore, the average particle diameter was found to increase 





Figure 13: Increased mean particle size (d. nm) with decreasing concentration via Method 1.  
 
 































Concentration of SiO2 (vol%)































Concentration of SiO2 (vol%)




The mean zeta potential of silica nanoparticles with unmodified surfaces in water increases 
with particle size (Metin, Baran, & Nguyen, 2012). Therefore according the data published by 
Metin et al. (2012) shown in Table 1, the LUDOX silica nanoparticles used in the dilutions of 
Methods 1 and 2 should carry a zeta potential between -48.7 mV to -79.8 mV depending the 
state of aggregation induced by the dilution. 
 
Particle Diameter Mean Zeta 
Potential 
5 nm -48.7 mV 
25 nm -60.3 mV 
75 nm -79.8 mV 
  
Table 1: Mean Zeta Potentials for non-surface functionalised silica nanoparticles in water. 
The zeta potential of each sample taken throughout the dilutions of Methods 1 and 2 are 
shown Figure 15 and 16 for methods 1 and 2 respectively. It can be seen that in both cases, 
the zeta potential of the colloidal silica became increasingly more negative as the dilutions 
were carried out. Although mean zeta potentials are a function of concentration, in this case 
the concentration is been reduced therefore, the increases in negative charge is primarily due 






Figure 15: Increased negative mean zeta potential with decreasing concentration via Method 1. 
 




















































In an article by T. Wang, Ni, Luo, Shou, and Cen (2012) it was noted that both size and pH 
can be found to significantly affect the viscosity of colloidal nanoparticle systems. The degree 
of aggregation caused by pH surface neutralisation and the shape in which the aggregates 
form are all contributing factor to increasing the viscosity of the system. However, the viscosity 
of the colloidal system diluted via Method 1 and 2 were in both found to decrease significantly 
with the relatively large quantities of water in which it was been mixed. Therefore, no increase 
in viscosity due to aggregation was observed. However, the rapidly decreasing viscosity of the 
system may have had an effect on the collision kinetics, resulting in aggregation. As shown in 
Figures 17 (Method 1) and 18 (Method 2), a strong trend can be observed between increases 
in particle size and decreases viscosity. This relationship seems to be more profound at very 
low centre poise viscosities, < 0.6 cP. This suggests that the less viscous nano-systems that 
were synthesised will exhibit a greater collision coefficient and therefore greater care must be 
given when introducing energy to the system in the tissue mimic synthesis method, Method 7. 
 
 
Figure 17: The relationship between viscosity and particle size as found during the 
investigations of Method 1. 
Highly dispersed nanoparticles have a zeta potential greater than + 30 mV or less than – 30 
mV (Abenojar et al., 2019). For nanoparticles within the +30 mV to -30 mV range, a lesser 
degree of electrostatic repulsion is experienced and therefore a greater probability of collision 


































Figure 18: The relationship between viscosity and particle size as found during the 
investigations of Method 1. 
Colloidal silica nanoparticles are stabilised by Si-OH salts therefore are basic in pH (~pH 10). 
Changes in pH, such as through the addition of gelatine (~pH 5) in Method 7 has the potential 
to neutralise the zeta potential of the colloidal silica and reduce its stability. The investigations 
carried out in Methods 2, 3 and 4 were to investigate the effects of inducing a more acidic 
environment on the stability of the colloidal silica. The measured mean zeta potentials of the 
colloidal silica that had been diluted using water of pH 10, pH 7 and pH 5 are shown in Figure 
19. The measurements were repeated at regular intervals over 7 days. As shown in Figure 
19, the mean zeta potential of the nano-system using pH 10 water was surprisingly less 




































Figure 19: Mean zeta potential over time. 
 
With a view to confirming the PSD provided by the dynamic light scattering, and for providing 
more structural information of the silica nanoparticles after diluting, the small angle x-ray was 
employed as Method 5.  However, the were a number of challenges that had to be overcome 
before any useful data could be collected. By far the biggest challenge experienced was down 
to the sealing of the glass capillaries. Two alternate methods of doing this were tried but both 
were relatively unsuccessful at creating a strong enough seal to withstand the vacuum 
chamber of the instrument. Therefore, out of the 14 samples that were tested, only 2 were 
able to provide useful data.  
The data collected via the small angle x-ray scattering instrument were for deionised water 
(used in the dilutions in Method 7) and a 1 vol% SiO2 that had been diluted from the stock 
LUDOX silica via Method 7. The x-ray scatter data collected from the water sample was 
subtracted from the 1 vol% colloidal silica to obtain information regarding its size, shape and 
surface. As shown in Figures 20 and 21, the degree of ‘scatter’ obtained from the water 
sample, depicted as the intensity of contrast, was significantly less than that obtained from the 
colloidal silica sample. The reference water scatter data was subtracted from the silica scatter 

































Figure 20: Low level scattering from water reference sample in the small angle x-ray employed 
as Method 6. 
 
Figure 21: High level of scattering from a 1 vol% colloidal SiO2 sample using a small angle x-ray 
 
The distribution of lengths of the silica nanoparticles within the sample were plotted, as shown 
as Figure 22. The distribution of lengths within the sample gave a very clear bell curve. This 
indicates that the silica nanoparticle was highly spherical in structure suggesting that a large 
fraction of nanoparticles within the diluted dispersant were not aggregated to form irregular 




square of intensity gave a highly linear curve. This indicates that the sample was highly 
monodispersed, consisting of ~8 nm particles. This size information is in agreement with the 
dynamic light scattering measurements made. 
Figure 22: P-R function of 1 vol% colloidal silica. 






The particle size distribution of the diluted LUDOX silica was measured to be 5-20 nm (d. nm). 
These particle sizes are ideal for the next stage of the investigation involving the high 
frequency ultrasound imaging. 
Limitations have arisen from the high failure rate of glass capillaries when placed under 
vacuum in the small angle x-ray. A possible recommendation for future work would be to 











Chapter 5: Results and discussion of the tissue mimic synthesis and 
the ultrasound measurements 
 
5.1.  Introduction 
 
The diluted colloidal silica is to be set into a semi-solid gelatine phase so that it can be fully 
submerged into the ultrasound measurements tank. The concentrations of colloidal silica, 
prepared in Methods 1-4 for the incorporation into the tissue mimic were; 1, 2, 3, 4, 8, 15, and 
20 vol%. During the incorporation into the tissue mimic, these concentrations were reduced to 
0.2, 0.4, 0.65, 0.88, 1.75, 3.28 and 4.38 vol% respectively. On synthesis of the tissue mimic, 
the particle size distribution was assessed once more to ensure no significant increases in 
particle size are introduced, compromising its monodispersed properties. 
The ultrasound attenuation data gained from the ultrasound measurements will be analysed 
in an attempt to identify any acoustic dependant behaviour that the nanoparticle may possess. 
 
5.2 Results and discussion 
 
Effects of temperature on the volume mean diameter (d. nm) of the silica nanoparticles was 
investigated using dynamic light scattering. The results from the measurements, shown in 
Figures 24 and 25 indicate that the heat energy applied to the colloidal system during tissue 
mimic synthesis will have little to no effect of the particle size distribution.  
However, many challenges did arise in the making of the silica-gelatine samples. Higher 
concentrations of colloidal silica exhibited a high degree of compatibility with the gelatine. 
Although lower concentrations were able to be mixed within the gelatine relatively easily, the 
higher concentrations showed a great deal of resistance to mixing. The formation of significant 
amounts of bubbles, even without mixing, lead to foaming and rapid cooling when placed 
inside the vacuum oven. Although there many researches and tissue mimic developers that 
use gelatine and agar on a regular basis, little to no effort seems to have been made in 
characterising the size of particles that they employ within them. This suggests that the drastic 
change in viscosity is due to the molecular interactions between silica and gelatine. The sol-
gel process is a well know nano synthesis process that manipulates the surface chemical 





Figure 24: Particle size distribution of colloidal silica after heating to 55C. 
 



















































The dynamic light scattering measurements taken of the gelatine/silica solution (prepared via 
Method 8) gave very consistent narrow distributions with low zeta potential, as shown in Figure 
26. 
 
Figure 26: Zeta potential distribution of 3 vol% silica in gelatine.  
In addition to this, the dynamic light scatterer was also able to identify a second population to 
that of the silica nanoparticles. As shown in Figure 27, the peak occurring at approximately 30 
d. nm is one that is in line with the previous measurements taken of the silica in water as 
opposed to gelatine. The larger peak shown to the right of Figure 27 corresponds to a 
population with a volume mean size of approximately 1000 nm, can be identified as gelatine. 
Therefore, the silica nanoparticles within the tissue mimic can be characterised with a particle 
size distribution of 10-100 nm. This size of nanoparticle is in line with the objectives outlined 





Figure 27: volume mean particles sizes of a co-population of SiO2 and gelatine particles. 
 
Although ultrasound attenuation is more accurately calculated by the difference between the 
front-face and back-face reflections, due to the high levels of noise experienced with the 
experimental setup as described in Method 9, the front and back-face reflections of the sample 
were unidentifiable. Therefore, the attenuation of acoustic energy through the sample was 
calculated by measuring the thickness of the samples by hand.  
A plot of attenuation with increasing concentrations of silica, as a function of frequency is 
shown in Figure 28. Although the broadband transducer was able to extend below and above 
the frequencies show, the standard error associated with data points was significantly high 
therefore, they were removed from any data analysis.  
Unsurprisingly, there was an overall increase in attenuation at higher frequencies and with 
increased concentration of nanoparticles. However, the concentrations used throughout these 
measurements are intentionally low. By demonstrating the ability to be highly attenuating at 
very low concentrations, enhances their ability to be detected at concentrations lower than 




































By isolating the attenuation data associated with each particular frequency, a change in the 
attenuation curve with increasing silica concentration occurs at above 45 MHz (as shown in 
Figure 29). However, this particular frequency dependency of silica concentration can be seen 
more prominently in Figure 30. In Figure 30, the attenuation observed with a reference gelatine 
sample containing no nanoparticles was measures and subtracted from each of the samples 
containing silica concentrations. The subtraction of the reference enabled the attenuation due 
to silica nanoparticle to be seen more clearly. As shown, for concentrations between 2.5 and 
4 vol%, the attenuation was significantly higher than that above or below this concentration. 
However, although the particle size distribution was assessed in this work, the particle 
distribution within the sample was not. For this type of acoustic dependency to be studied in 







































Figure 30: reference attenuation subtracted from sample attenuation and plotted as a function 




The particle size distribution was characterised within the gelatine sample to have a mean size 
of 10-100nm. This size range meets one the objectives of the work. However, the incorporation 
of silica nanoparticles into gelatine-based tissue mimics has presented a number of 
challenges. A suggestion for future work would be to study the use of nanoparticles (10-100 































Nano-sized particles between 10-100nm were employed in this work to investigate the 
acoustic properties of a specific type nanoparticle material. The particle size distribution of the 
particles within a tissue mimic was characterised and used to implement a number of acoustic 
measurements. The ultrasounds attenuation data acquired did not show any direct link to a 
material specific property of the nanoparticle however, the development of the early stage 
experimental design carried out in this work was demonstrated to provide the acoustic data 





7.0 Recommendations for Future Work 
 
In order to achieve an accousticly accurate tissue mimic with correct density and speed of 
sound, a concentration of 8 wt.% gelatine was used in this work. The viscosity of the gelatine-
silica system produced via Method 7 was found to significantly increase with increasing 
concentration of colloidal silica used in the preparation. As a result, large volumes of air were 
able to become trapped within the sample. The air within the sample therefore significantly 
increasing the degree of noise experienced on collecting attenuation data via Method 9 and 
were therefore unable to be used. Therefore, the interactions between the gelatine and 
colloidal silica used in this work suggests that an alternative setting agent such as agar may 
be a better alternative for tissue mimic synthesis with colloidal silica NPs. 
In addition to this, the introduction of nano and micron sized particles to more accurately 
represent the natural acoustic scatter signature of human tissue will enable more accurate 
and representative data to be collected. 
 
Most of the samples prepared for the small angle x-ray data collection via Method 6 were 
unsuccessful and ruptured under the vacuum of the sample chamber. The glass capillaries 
used were sealed using two separate techniques however, both were found to be relatively 
unsuccessful. Further development of these techniques is required if particle information is to 
be acquired via this analytic technique. 
The use of an additional analytical technique such as SEM may also be used to further support 
the dynamic light scattering data obtained in this work however, the use of a biological samples 
such as those containing gelatine or agar in an SEM may present its own limitations due to 
the risk of contaminating the equipment. 
 
Further tissue mimic development as suggested above, in addition to particle size distribution 
mapping and particle size characterisation would enable more accurate attenuation data to be 
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